Publications

Original Research

  • Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Tomakh N, Skrypchenko I, Muehler AR. A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neurol 2022; 9:977-87 (full text).
  • Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. Neurology 2021; 96:e376-86 (full text).
  • Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Kappos L. Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Mult Scler 2021; 27:1564-76 (full text).
  • Derfuss T, Sastre-Garriga J, Montalban X, Rodegher M, Wuerfel J, Gaetano L, Tomic D, Azmon A, Wolf C, Kappos L. The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin 2020; 6:2055217320907951 (full text).
  • Hagerman R, Jacquemont S, Berry-Kravis E, Des Portes V, Stanfield A, Koumaras B, Rosenkranz G, Murgia A, Wolf C, Apostol G, von Raison F. Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Sci Rep 2018; 8, DOI 10.1038/s41598-018-34978-4 (abstract).
  • Kappos L, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S; Scherz T, Wolf C, Wallström E, Dahlke F. Siponimod versus placebo in secondary progressive multiple sclerosis: a double-blind randomised, phase 3 study. Lancet. 2018; 391:1263–73 (full text).
  • Selmaj K, Barkhof F, Belova AN, Wolf C, van den Tweel ER, Oberyé JJ, Mulder R, Egging DF, Koper NP, Cohen JA. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Mult Scler. 2017; 23:1909–17 (full text).
  • Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. A Randomized Clinical Trial. JAMA Neurol. 2015; 72:1433–41 (full text).
  • Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Täubel J, Bennett B. Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. PLoS One. 2013; 8:e58438 (full text).
  • Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012; 83:282–7 (abstract).
  • Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010; 81:907–12 (abstract).
  • Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A. Long-term follow-up of the original interferon-β1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clin Ther 2009; 31:1724–36 (abstract).
  • Zipp F, Hartung HP, Hillert J, Schimrigk S, Trebst C, Stangel M, Infante-Duarte C, Jakobs P, Wolf C, Sandbrink R, Pohl C, Filippi M. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006; 67:1880–3 (abstract).
  • Bast T, Völp A, Wolf C, Rating D. The Influence of Sulthiame on EEG in Children with Benign Childhood Epilepsy with Centrotemporal Spikes (BECTS). Epilepsia 2003; 44:215–20 (full text).
  • Madeja M, Wolf C, Speckmann EJ. Reduction of voltage-operated sodium currents by the anticonvulsant drug sulthiame. Brain Research 2001; 900:88–94 (abstract).
  • Tergau F, Wischer S, Wolf C, Paulus W. Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine. Mov Disord 2001; 16:731–5 (abstract).
  • Rating D, Wolf C, Bast T. Sulthiame as Monotherapy in Children with Benign Childhood Epilepsy with Centrotemporal Spikes: A 6-Month, Multicentre, Double-Blind, Placebo-Controlled Study. Epilepsia 2000; 41:1284–8 (full text).
  • Wangemann M, Wolf C, Retzow A. Replacement of oral valproate with intravenous valproate: a study on dose finding and bioavailability. Eur J Clin Res 1997; 9:209–15.
  • Wolf C, Borch M, Düsing R, Grünes JU, Kinze W, Krüger H. Antiepileptische Pharmakotherapie mit einer retardierten Carbamazepinformulierung. Psychopharmakotherapie 1996; 3:72–6.
  • Gottesleben A, Willemsen D, Wolf C. Retardiertes Carbamazepin in der Therapie des alkoholischen Prädelirs. Akt Neurologie 1995; 22:60–5 (abstract).
  • Wolf C, Borch M, Düsing R, Grünes JU, Kinze W, Krüger H. Antiepileptic pharmacotherapy with a slow-release carbamazepine formulation. Ceska Slov Neurol Neurochir 1995; 91:139–43.
  • Gottesleben A, Wolf C, Willemsen D. Slow-release carbamazepine for therapy of alcoholic predelirium. Eur J Clin Res 1994; 5:51–61.
  • Wolf C. Die renale Zellauscheidung unter extremen Diuresebedingungen. Untersuchungen zum quantitativen Harnsediment. Inaug Diss Hamburg 1991 (full text).

Consensus, Opinion, and Position Papers

  • Brownlee WJ, Wolf C, Hartung HP, Dingermann T, Anshasi N, Clark RA, Trojano M, Selmaj K, Uitdehaag BM, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel M, Bobrovnikova O, Cohen JA. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Mult Scler 2022 Aug 24:13524585221116269. Epub ahead of print (abstract).
  • Berelowitz KS, Wolf C, Täubel J. Benefits of a single versus multicenter approach in early-phase patient studies. A case study of multiple sclerosis patients. Monitor (Assoc Clin Pharmacol). 2011; 25(10):21–5 (full text).
  • Teunissen CE, Bennett JL, Berven FS, Comabella M, Franciotta D, Federiksen JL, Fleming J, Furlan R, Giovannoni G, Hintzen RQ, Johnson MH, Krasulova E, Kuhle JK, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Wolf C, Tumani H, Hemmer B, Deisenhammer F. Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis. J Lab Med. 2010; 34:1–12 (abstract).
  • Teunissen CE, Tumani HT, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan F, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Hemmer B, Deisenhammer F, Giovannoni G. Short commentary on ‘a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking’. Mult Scler 2010; 16:129–32 (abstract).
  • Teunissen CE, Bennett JL, Berven FS, Comabella M, Franciotta D, Federiksen JL, Fleming J, Furlan R, Giovannoni G, Hintzen RQ, Johnson MH, Krasulova E, Kuhle JK, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Wolf C, Tumani H, Hemmer B, Deisenhammer F. A consensus protocol for standardisation of CSF sampling and biobanking in multiple sclerosis. Neurology 2009; 73:1914–22 (abstract).

Reviews and Textbook Chapters

  • Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C. Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? Front Neurol 2022; 13:844873 (full text).
  • Arends RJ, Wang D, Buurman M, Luten J, Koper NP, Wolf C, Scheren M. Comparison of Copaxone® and Synthon’s therapeutically equivalent glatiramer acetate. Pharmazie. 2019; 74:449-61 (open access).
  • Wolf C, Loerbroks T, Berdien E. Erfahrungen mit intravenösem Natriumvalproat. Notarzt 1998; 14:94–8.
  • Wolf C. Медикаментозное лечение эпилепсий [Pharmacotherapy of Epilepsy]. In: Temin P, Nikanorova M (eds). Диагностика и лечение эпилепсий у детей. [Diagnosis and Treatment of Childhood Epilepsy]. Moscow: Mozhaysk-Terra 1997 (full text in Russian).
  • Wolf C. Biopharmaceutical aspects of selected neuropsychopharmacologic drugs and their therapeutic and economic impact. Ceska Slov Neurol Neurochir 1995; 91:131–8.

Lectures and Published Abstracts

  • Brownlee WJ, Wolf C, Hartung HP, Dingermann T, Anshasi N, Trojano M, Selmaj K, Uitdehaag BMJ, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel MB, Bobrovnikova O, Cohen JA. Towards affordable medicines: consensus recommendations on follow-on disease-modifying drugs for multiple sclerosis. Annual Conference of the European Multiple Sclerosis Platform (EMSP) 2023, Helsinki (poster).
  • Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Stoyanov Bozhinov P, Tomakh N, Skrypchenko I, Muehler AR. Assessment of dose-dependency of anti-inflammatory and neuroprotective efficacy variables and biomarkers for vidofludimus calcium in emphasis: a randomized, placebo-controlled phase 2 trial in relapsing-remitting multiple sclerosis.  38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2022, Amsterdam. O120 (abstract). 
  • Brownlee WJ, Wolf C, Hartung HP, Dingermann T, Anshasi N, Trojano M, Selmaj K, Uitdehaag BM, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel MB, Bobrovnikova O, Cohen JA. Consensus recommendations on the use of follow-on disease-modifying treatments for multiple sclerosis. 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2022, Amsterdam. P339 (poster).
  • Benedict RHB, Tomic D, Fox R, Cree BAC, Vermersch P, Giovannoni G, Bar-Or A, Gold R, Ritter S, Karlsson G, Wolf C, Kappos L. Siponimod Improves Cognitive Processing Speed in Patients With Secondary Progressive Multiple Sclerosis: EXPAND Subgroup Analyses. Poster P22, IMSCOGS 2019, Amsterdam (full text).
  • Kappos L, Vermersch P, Cree B, Benedict R, Giovannoni G, Bar-Or A, Gold R, Arnould S, Rouyrre N, Karlsson G, Piani Meier D, Dahlke F, Wolf C, Tomic D, Fox R. A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis. Oral Presentation S12.006, AAN 2019, Philadelphia. Neurology. 2019; 92 (15 Supplement, abstract).
  • Benedict R, Fox R, Tomic D, Cree B, Vermersch P, Giovannoni G, Bar-Or A, Gold R, Ritter S, Karlsson G, Wolf C, Kappos L. Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis. Poster P3.2-051, AAN 2019, Philadelphia. Neurology 2019; 92 (15 Supplement, full text)
  • Fox R, Arnold DL, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H, Sidorenko T, Wolf C, Tomic D, Dahlke F, Kappos L. Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study. Oral presentation 129, ECTRIMS 2017, Paris (abstract).
  • Kappos L, Vermersch P, Bar-Or A, Gold R, Fox R, Cree B, Magnusson B, Rouyrre N, de Vera A, Wolf C, Dahlke F, Giovannoni G. Efficacy of siponimod on disability progression in SPMS patients with and without on-study relapses. Poster P782, ECTRIMS 2017, Paris (abstract).
  • Gold R, Giovannoni G, Cree B, Vermersch P, Fox R, Bar-Or A, Magnusson B, Rouyrre N, Tomic T, Wolf C, Dahlke F, Leppert D, Kappos L. Impact of primary endpoint definitions and patient baseline characteristics on study outcomes in progressive multiple sclerosis. Poster P1239, ECTRIMS 2017, Paris (abstract).
  • Vermersch P, Bar-Or A, Cree B, Fox F, Giovannoni G, Gold R, Arnould S, Wallström E, Sidorenko T, Wolf C, Dahlke F, Kappos L. The EXPAND Study Results: Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis. Oral presentation EAN 2017, Amsterdam.
  • Giovannoni G, Bar-Or A, Cree B, Fox R, Gold R, Vermersch P, Pohlmann H, Wallström E, Wolf C, Dahlke F, Sidorenko T, Kappos L. The EXPAND Study Results: Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis. ePresentation EAN 2017, Amsterdam (full text).
  • Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Arnould S, Sidorenko T, Wolf C, Wallström E, Dahlke F. Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study. Platform presentation at AAN 2017, Boston (abstract).
  • Fox R, Kappos L, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H, Wolf C , Dahlke F, Wallström E, Sidorenko T. Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis. Oral presentation at AAN 2017, Boston (abstract).
  • Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Arnould S, Sidorenko T, Wolf C, Wallström E, Dahlke F. Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study. ECTRIMS 2016, London; P1050 (abstract).
  • Hagerman RJ, Hessl D, Berry-Kravis E, Jacquemont S, des Portes V, Wolf C, Apostol G, Koumaras B, Stanfield A, von Raison F. (2015). Can we reverse intellectual and behavioral problems in adults with FXS? 18th SSBP International Research Symposium 2015; London. J Intell Disab Res 2015; 59:791 (abstract).
  • Cohen JA, Belova A, Barkhof F, Wolf C, van den Tweel ERW, Oberyé JJL, Mulder R, Koper NP, Selmaj K. Switching from branded to generic glatiramer acetate: two-year clinical data from the GATE trial further support the continued efficacy and tolerability of generic glatiramer. ECTRIMS 2015, Barcelona; P1050 (full text).
  • Wiendl H, Dahlke F, Bennett D, Rosenkranz G, Wolf C, Bar-Or A. IL-17 neutralization by subcutaneous CJM112, a fully human anti IL-17A monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis: study design of a phase 2 trial. ECTRIMS 2015, Barcelona; P655 (full text).
  • Barkhof F, Belova A, Selmaj K, Wolf C, van den Tweel EWR, Oberyé JJL, Mulder R, Koper NP, Cohen JA. Switching from branded to generic glatiramer acetate: two-year MRI data from the GATE trial demonstrates continuous efficacy. ECTRIMS 2015, Barcelona; P522 (full text).
  • Selmaj K, Barkhof F, Wolf C, Belova A, Oberye J, van den Tweel E, Mulder R, Koper N, Voortman, G Cohen J. Similar Local Tolerability Profiles Following Double-Blind Treatment With Generic or Branded Glatiramer Acetate in Multiple Sclerosis. Neurology 2015: 84 (Suppl). P3.256 (abstract, full text).
  • Cohen JA, Belova A, Selmaj K, Wolf C, Oberyé JJL, van den Tweel ERW, Koper NP, Voortman G, Barkhof F. Generic glatiramer acetate is equivalent to copaxone on efficacy and safety: results of the randomized double-blind GATE trial in multiple sclerosis. Mult Scler 2014; 20 (Suppl 1):38-9 (abstract, full text).
  • Derfuss T, Verdun di Cantogno E, Wolf C, Zhang Y, Blankenbiller T, Kappos L. A cross-sectional (ACROSS), long-term follow-up of patients enrolled in the fingolimod phase II program in relapsing multiple sclerosis. Joint Congress of European Neurology Istanbul 2014. Poster PP4185 (full text).
  • Green AJ, Sergott RC, Bennett JL, Hamilton SR, Costello F, Dahlke F, Tomic D, Knice K, Wolf C. Fingolimod for the treatment of acute optic neuritis: design of a Phase II study (ADONIS). ECTRIMS Copenhagen 2013. Poster P570 (abstract, full text).
  • Wolf C. Arzneimittelentwicklung bei MS: Methodik – regulatorischer Rahmen – Ausblick. Jahreskongress Klinische Pharmakologie. Düsseldorf 2013 (full text).
  • Polman C, Bowen J, Barkhof F, Bates D, Wynn D, Sanders EACM, Wolf C, Morris T, Duda P, Weinkauf B, Lynn F, Bennett B. Double-Blind, Placebo-Controlled Randomized Phase II Serial MRI, Safety and Tolerability Study of Two Doses of CDP323 in Subjects with Relapsing Forms of Multiple Sclerosis over 24 Weeks. AAN Annual Meeting Toronto 2010. Platform presentation S21.002 (abstract).
  • Ebers G, Rice G, Wolf C, Traboulsee A, Langdon D, Kaskel P, Salazar-Grueso E. 16-year long-term follow-up of interferon beta-1b treatment of patients with multiple sclerosis. J Neurol 2005; 252 (Suppl 2):130.
  • Langdon D, Reder A, Cox D, Kaskel P, Ebers G, Kaskel P, Wolf C, Salazar-Grueso E, Miltenburger C. Health-related quality of life interferon beta-1b treatment in MS: current evidence and long-term perspectives. J Neurol 2005; 252 (Suppl 2):65.
  • Langdon D, Lapierre Y, Ebers G, Kaskel P, Traboulsee A, Hum S, Wolf C, Salazar-Grueso E, Miltenburger C. Long-term MS Treatment with IFNB-1 b: Bringing Cognition into the Evaluation. Neuroepidemiology 2005; 24:177.
  • Traboulsee A, Li D, Zhao G, Paty D, Ebers G, Langdon D, Wolf C, Wagner K, Salazar-Grueso E. Methodology for longitudinal and cross-sectional MRI evaluation of patients treated long-term with IFNB1b. Neurology 2005; 64 (Suppl 1):A385.
  • Ebers G, Rice G, Wolf C, Traboulsee A, Langdon D, Kaskel P, Salazar-Grueso E. 16-Year long-term follow-up of interferon beta-1b treatment in RRMS. Neurology 2005; 64 (Suppl 1):A241.
  • Ebers G, Rice G, Traboulsee A, Langdon D, Kaskel P, Wolf C, Salazar-Grueso E. Long-term follow-up of interferon beta-1b pivotal trial RRMS patients - Design issues of a 16-year follow-up study. Mult Scler 2004; 10 (Suppl 2):S247.
  • Wolf C. Sulthiame: A Re-Emergent Treatment Option in Epilepsy? 11ème Colloque Lausannois d'Epileptologie. Lausanne 2000.
  • Rating D, Bast T, Wolf C. Sulthiame vs placebo in treatment of benign epilepsy with centrotemporal spikes ("Rolandic" epilepsy). Eur J Paed Neurol 1999; 3:A44.
  • Rating D, Wolf C. Sultiam vs. Plazebo in der Behandlung der benignen Partialepilepsie mit centrotemporalen spikes (BECTS; Rolando-Epilepsie). Mschr Kinderheilk 1999; 147:885.
  • Rating D, Wolf C. Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("Rolandic" epilepsy). Epilepsia 1999; 40 (Suppl 6):163.
  • Wolf C, Müller-Oerlinghausen B, Retzow A. Treatment of acute manic episodes with valproate as an adjunct to neuroleptic medication. Skandinavisk Selskap for Biologisk Psykiatri. Oslo 1998.
  • Berky M, Wolf C, Kovács G. Carbamazepine versus lithium in bipolar affective disorders. A randomised, double-blind one-year study in 168 patients followed by an open prolongation of one year. Eur Arch Psychiatry Clin Neurosci 1998; 248:S119 (full text).
  • Tergau F, Wischer S, Wolf C, Paulus W. Treatment of restless legs syndrome with α-dihydroergocryptine. Mov Disord 1998; 13 (Suppl 2):292.
  • Kovács G, Donászy M, Kassai Á, Bartkó G, Magyar IG, Ostorharics, G, Hullám I, Berky M, Wolf C. Karbamazepin versus líthium a bipoláris affektív betegségek profilaxisában. Magyar Pszichiátriai Társaság. IV Nemzeti Kongresszus. 1998, p 209.
  • Wolf C, Berky M, Kovács G. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorders. A randomised, double-blind 1-year study in 168 patients. Eur Neuropsychopharmacol 1997; 7 (Suppl 2):S176 (full text).
  • Temin P, Kalinina L, Nikanorova M, Mukhin K, Sprekher B, Litvin A, Perminov V, Belousova E, Ermakov A, Wolf C. Antiepileptic monotherapy with carbamazepine in children using two different galenic formulations. 3rd Baltic Child Neurology Congress, Palanga 1995.
  • Wolf C, Retzow A, Giermann D. Sultiam in der Therapie benigner fokaler Epilepsien. 34. Jahrestagung der Deutschen Sektion der Internationalen Liga gegen Epilepsie, Köln 1994. Epilepsie-Blätter 1994; 7 (Suppl):40.
  • Wolf C, Schulz M, Düsing R. Pharmacotherapy of benign partial epilepsy in childhood. 2nd Baltic Child Neurology Congress, Riga 1993.
  • Kröger K, Wolf C, Kaufmann J. Neue Erkenntnisse zur quantitativen Zellausscheidung im Urin. Urologe; 1990; 29 (Suppl):A107.

Letters

  • Cohen JA, Wolf C, Selmaj K, Arends R. Follow-on glatiramer acetate. Letter to editor. eNeurologicalSci 2018; DOI 10.1016/j.ensci.2018.11.019 (full text)

Patents

  • Cha JH, Dahlke D, Gardin A, Legangneux E, Malanga CJ III, Shakeri-Nejad K, Wallström E, Wolf C. Dosing Regimen of Siponimod. US Patent App. 16/651931 (full text).
  • Cha JH, Dahlke D, Gardin A, Legangneux E, Malanga CJ III, Shakeri-Nejad K, Wallström E, Wolf C. Dosing Regimen of Siponimod. US Patent App. 16/651,954 (full text).

Acknowledgements

  • Davenport RJ, Munday JR. Blocking alpha4-integrins - A small molecule approach to treatment of multiple sclerosis. J Neurol Sci 2008; 274:27–30 (abstract).

   Follow me on ResearchGate